WGS Stock Forecast & Price Target

GeneDx Holdings is viewed positively because Carelon’s updated outpatient genome coverage policy should reduce reimbursement uncertainty and support a structural shift from exome to genome sequencing, with the mix already rising to 47% of volumes at Q4'25 from 23% at Q3'23. The company’s 2026 growth drivers include 30%+ WES/WGS volume growth, a near tripling of the sales force to about 160 reps from roughly 60, and expansion into a large pediatrician market sized at $2.6 billion, while the $33 million Fabric Genomics acquisition adds AI-powered interpretation capabilities and potential international revenue. Additional upside comes from breakthrough-device momentum, AAP guideline support, and GUARDIAN data showing 3.7% positive newborn screenings and a 92% confirmed diagnosis rate for nonstandard conditions, reinforcing the long-term case for broader adoption and margin expansion.

GeneDx Holdings is facing a weaker fundamental setup because Q1'26 revenue of $102M, adjusted gross margin of 68.5%-69%, and adjusted net income of negative $8M all missed expectations despite WES/WGS volume growth of 34% Y/Y, showing that volume gains are not translating cleanly into profitability. Management then cut 2026 revenue guidance by $65M to $475M-$490M, reduced core exome and genome growth to 20%+ and volume growth to 30%+, and cited hits from ARR, lower expansion market volumes, and non-core softness, which raises concern about forecasting credibility and execution. Although cash ended Q1'26 at $172M and adjusted net income is still expected to turn positive later, the combination of ASP pressure near $3,300, mix-related reimbursement headwinds, and reduced 2028 adjusted net income to $25M points to a more fragile earnings trajectory than previously assumed.